Login to Your Account



Enanta Lands $42.7M in NIAID Funds for Bicyclolide Antibiotic

By Catherine Shaffer


Friday, October 14, 2011
Enanta Pharmaceuticals Inc. is banking on bicyclolides with a new $42.7 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support five years of development of the drugs as medical countermeasures against biodefense category A and B bacteria.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription